Boston Scientific (BSX) BT Study On Asthma Results Positive
Zacks Investment Research | May 24, 2017 10:06PM ET
Medical device major Boston Scientific Corporation (NYSE:BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study. The evaluation confirmed that BT procedure performed with Boston Scientific’s Alair System reduces complications in adult patients with severe persistent asthma. The dataset was presented at the American Thoracic Society Conference in Washington, DC.
Asthma, a chronic inflammatory disease of breathlessness, currently affects more than 25 million people and approximately 10% of the cases are considered severe. For patients with severe asthma, even the highest dose of standard medications may not alleviate the risk of frequent and life-threatening asthma attacks. Management claims that BT is an established treatment that can transform the lives of people with severe asthma.
Meanwhile, for the last one month, Boston Scientific has been performing reasonably well in terms of price. The company’s share price has been trading above the Zacks categorized Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.